Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioTime and its wholly-owned subsidiary Embryome Sciences have signed a letter of intent with International Stem Cell and its wholly-owned subsidiary Lifeline Cell Technology to jointly produce and distribute a wide array of research products from human embryonic stem cell technology.
Subscribe to our email newsletter
Under a collaborative production and manufacturing agreement, the parties intend to manufacture ESpy cell lines, as well as a host of supplies scientists will utilize in the field of stem cell research. The progenitor cell lines will be produced and distributed in joint efforts utilizing Embryome Science’s proprietary Embryomics technology, its future Embryome.com online database, and technology and approved hES cell lines licensed from the Wisconsin Alumni Research Foundation (WARF). Lifeline will contribute its manufacturing and quality control expertise.
Jeffrey Janus, CEO of Lifeline and a founding member of Clonetics, said: “Lifeline’s and Embryome Sciences’s combined strengths and technologies will give scientists access to the basic research tools they will need to take the field of regenerative medicine to the next level.”